Frequency report of irinotecan toxicity in Iranian population: Is genomic differences responsible?

Date 28 June 2017
Event ESMO World Congress on Gastrointestinal Cancer 2017
Session ESMO World Congress on Gastrointestinal Cancer 2017
Topics Gastrointestinal Cancers
Palliative and Supportive Care
Presenter Maliheh Nejati
Citation Annals of Oncology (2017) 28 (suppl_3): iii13-iii136. 10.1093/annonc/mdx261
Authors M. Nejati, A. Derakhshndeh
  • /


Irinotecan is a drug of choice as monotherapy or in combination for treatment of some cancers including colorectal, esophageal/gastric and etc. Its use is limited by severe toxicities such as neutropenia and diarrhea. These adverse effects negatively impact therapeutic outcomes and delay subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation. Genotyping of UGT1A1 may help predicting serious toxicities of irinotecan in more sensitive patients and modify the starting dose. Incidences of toxicities and frequency of different genotypes of UGT1A1 differs among worldwide ethnicities. We aimed to assess the prevalence of irinotecan induced neutropenia and diarrhea during past one year in one of referral hematology-oncology center in Iran. We also reviewed the related data of irinotecan toxicity and its relation to UGT 1A1 enzyme polymorphisms.